查詢結果分析
來源資料
相關文獻
- Utility Assessment for Different Clinical Phases of Breast Cancer in Taiwan
- 臺灣地區乳癌成因研究簡介
- Disability-Adjusted Life Years for Breast Cancer Patients in Taiwan
- Immunohistochemical Analyses of p53 Protein Expression in Breast Cancers in Taiwan: A Clinicopathologic Study
- 以醫療品質的觀點探討臺灣乳癌之診療型態
- 從美國婦癌醫學會(SGO)第34屆年會談臺灣婦女乳房健康照顧的未來趨勢
- 臺灣乳癌的研究
- Evaluating the Effectiveness of the Coal Ash Artificial Reefs at Wan-Li, Northern Taiwan
- 記臺灣蘭科植物相新記錄種--緣毛松蘭
- 臺灣的氣候變化--氣溫和降水
頁籤選單縮合
題名 | Utility Assessment for Different Clinical Phases of Breast Cancer in Taiwan=臺灣乳癌不同臨床階段效用指標評估 |
---|---|
作 者 | 季瑋珠; 黃俊升; 陳人豪; 張金堅; | 書刊名 | 臺灣醫學會雜誌 |
卷期 | 99:9 2000.09[民89.09] |
頁次 | 頁677-683 |
分類號 | 416.226 |
關鍵詞 | 臺灣; 乳癌; 效用指標評估; Quality of life; Breast cancer; Utility assessment; Delphi technique; Time trade-off; Standard gamble; Visual analog scale; |
語文 | 英文(English) |
英文摘要 | Background and purpose; Utility is an important index of health-related quality of life (HRQoL). The purpose of this study was to assess utility in different clinical phases of breast cancer in patients in Taiwan. Methods: Based on a review of HRQoL literature pertaining to breast cancer and medical records of 979 breast cancer patients admitted to National Taiwan University Hospital from 1991 to 1995, a semi-open checklist describing the diagnosis and treatment activities and impacts of different clinical phases of breast cancer was constructed. The checklist was then reviewed and revised in consulation with surgeons, medical oncologists, radiation oncologists, nurses, and breast cancer patients. Thirty-one clinical and public health experts were invited to assess the utility of each phase with the visual analog scale (VAS), standard gamble (SG), and time trade-off (TTO) methods, according to the description of the average patient's life in the checklist. The Delphi technique was used to reach expert consensus. Results: The VAS utility scores were highest during screening phase (100 or 90). Lower in phases of incidental finding of a tumor (75) and diagnosis (70),a and lower still in the initial treatment phases, especially during adjuvant chemotherapy (50). The scores improved during the follow-up phases. There was a higher score for breast-conserving surgery (65) than modified radical mastectomy (60) only in the early follow-up phase. The scores for recurrence or metastasis (30) and terminal stage were considerably lower and reached the lowest level (10 in a general ward and 12.5 at home or in a hospice) among all phases. The utility scores assessed by SG and TTO were higher than those assessed by VAS. Conclusions: In this study, we established a consensus among clinical and public health experts on the impact of different clinical phases of breast cancer on utility. The results of this study may be useful in cross-cultural comparisons and cost-utility analyses for breast cancer. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。